M&A Deal Summary

ADVANZ PHARMA Acquires Eisai - Two Medicines

On April 1, 2019, ADVANZ PHARMA acquired life science company Eisai - Two Medicines from Eisai for 33M USD

Acquisition Highlights
  • This is ADVANZ PHARMA’s 3rd transaction in the Life Science sector.
  • This is ADVANZ PHARMA’s 5th largest (disclosed) transaction.
  • This is ADVANZ PHARMA’s 3rd transaction in the United States.
  • This is ADVANZ PHARMA’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2019-04-01
Target Eisai - Two Medicines
Sector Life Science
Buyer(s) ADVANZ PHARMA
Sellers(s) Eisai
Deal Type Divestiture
Deal Value 33M USD

Target

Eisai - Two Medicines

Woodcliff Lake, New Jersey, United States
Eisai, Inc. - Two Medicines (Salagen & Panretin) is a pharmaceutical business, Salagen® indications include the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck, and the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome. Panretin® indications include the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma (KS).

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ADVANZ PHARMA

London, United Kingdom

website

Category Company
Sector Life Science
Employees630
Revenue 508M USD (2019)
DESCRIPTION

ADVANZ PHARMA is a specialty pharmaceutical company with a strategic focus on complex medicines with direct sales access in Europe and a global distribution network. ADVANZ PHARMA is based in London, England.

DEAL STATS #
Overall 5 of 6
Sector (Life Science) 3 of 4
Type (Divestiture) 3 of 3
State (New Jersey) 1 of 1
Country (United States) 3 of 3
Year (2019) 1 of 1
Size (of disclosed) 5 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-10-05 Concordia Pharmaceuticals - Frotaz Zinacef ad Zantac Injection

Oakville, Ontario, Canada

Fortaz®, ZinacefTM, and Zantac® Injection are the products used in specialty generic pharma.

Sell $10M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-03-16 Correvio Pharma

Vancouver, British Columbia, Canada

Correvio Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Correvio Pharma is headquartered in Vancouver, Canada.

Buy $76M

Seller(S) 1

SELLER

Eisai

Woodcliff Lake, New Jersey, United States

website

Category Company
Founded 1995
Sector Life Science
DESCRIPTION

Eisai, Inc. is a pharmaceutical company focuses on neurology, gastrointestinal disorders and oncology/critical care.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Divestiture) 2 of 2
State (New Jersey) 2 of 2
Country (United States) 2 of 2
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-30 AkaRx

Paramus, New Jersey, United States

AkaRx, Inc. is a developer of Avatrombopag drug. Avatrombopag is an investigational oral thrombopoietin receptor agonist.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-06 C2N Diagnostics

St. Louis, Missouri, United States

C2N provides clinical laboratory services and advanced diagnostic solutions in the field of brain health. The company's high-resolution mass spectrometry-based biomarker services and products are used for clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N is based in St. Louis, Missouri.

Buy -
Mergr

Product

Company

Legal